Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - posaconazole, quantity: 100 mg - tablet, enteric coated - excipient ingredients: hyprolose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; hypromellose acetate succinate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - posaconazole -

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - posaconazole 100mg;   - modified release tablet - 100 mg - active: posaconazole 100mg   excipient: colloidal silicon dioxide croscarmellose sodium hyprolose methacrylic acid - ethyl acrylate copolymer microcrystalline cellulose opadry yellow 85f520152 propyl gallate sodium stearyl fumarate triethyl citrate xylitol - posaconazole juno is indicated for use in the treatment of the following invasive fungal infections in patients 18 years of age or older: - invasive aspergillosis in patients with disease that is refractory to, or are intolerant of, amphotericin b, itraconazole or voriconazole. - oesophageal candidiasis or candidemia in patients with disease that is refractory to, or who are intolerant of, amphotericin b, fluconazole, or itraconazole. - fusariosis, zygomycosis, cryptococcosis, chromoblastomycosis, and mycetoma in patients with disease refractory to other therapy, or patients who are intolerant of other therapy. - coccidioidomycosis posaconazole juno is also indicated for the prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - posaconazole, quantity: 40 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; sodium citrate dihydrate; citric acid monohydrate; titanium dioxide; glycerol; xanthan gum; liquid glucose; peg-40 hydrogenated castor oil; purified water; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; flavour - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: ? treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.